U.S. patent number RE36,939 [Application Number 08/652,690] was granted by the patent office on 2000-10-31 for composition for therapy of diseases with ultrasonic and pharmaceutical liquid composition containing the same.
This patent grant is currently assigned to EKOS Corporation. Invention is credited to Katsuro Tachibana, Shunro Tachibana.
United States Patent |
RE36,939 |
Tachibana , et al. |
October 31, 2000 |
**Please see images for:
( Certificate of Correction ) ** |
Composition for therapy of diseases with ultrasonic and
pharmaceutical liquid composition containing the same
Abstract
A booster comprising a plenty of microbubbles of a gas in a
liquid, e.g. about 4.times.10.sup.7 cells/ml of microbubbles of a
gas having a diameter of 0.1 to 100 .mu.m in a 3 to 5% human serum
albumin solution, and a pharmaceutical liquid composition
comprising the booster as set forth above and a medicament, which
are useful for the therapy of various diseases together with
exposure of ultrasonic, where the therapeutic effects of the
medicament is enhanced by the application of ultrasound in the
presence of the booster.
Inventors: |
Tachibana; Katsuro (Fukuoka,
JP), Tachibana; Shunro (Fukuoka, JP) |
Assignee: |
EKOS Corporation (Bothell,
WA)
|
Family
ID: |
13099707 |
Appl.
No.: |
08/652,690 |
Filed: |
May 30, 1996 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
Reissue of: |
855545 |
Mar 20, 1992 |
05315998 |
May 31, 1994 |
|
|
Foreign Application Priority Data
|
|
|
|
|
Mar 22, 1991 [JP] |
|
|
3-058970 |
|
Current U.S.
Class: |
604/22; 424/94.6;
424/94.63; 601/2 |
Current CPC
Class: |
A61K
9/0009 (20130101); A61K 9/5052 (20130101); A61K
41/0004 (20130101); A61K 41/0028 (20130101); A61K
41/0047 (20130101); A61K 49/223 (20130101) |
Current International
Class: |
A61K
41/00 (20060101); A61K 9/00 (20060101); A61K
9/50 (20060101); A61K 49/22 (20060101); A61B
008/00 () |
Field of
Search: |
;604/22 ;601/2
;424/9,450,9.5-9.52,94.1,94.6,94.63 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
634470 |
|
Feb 1993 |
|
AU |
|
0 224 934 A2 |
|
Jun 1987 |
|
EP |
|
0 278 074 A2 |
|
Aug 1988 |
|
EP |
|
0327490 |
|
Aug 1989 |
|
EP |
|
0278074 |
|
Mar 1990 |
|
EP |
|
52115591 |
|
Sep 1977 |
|
JP |
|
2180275 |
|
Jul 1990 |
|
JP |
|
15 77551 |
|
Oct 1980 |
|
GB |
|
WO80/02365 |
|
Nov 1980 |
|
WO |
|
WO89/05159 |
|
Jun 1989 |
|
WO |
|
WO89 05160 |
|
Jun 1989 |
|
WO |
|
WO90/01971 |
|
Mar 1990 |
|
WO |
|
Other References
Vanderberg et al., Am. Heart J., 11574, 733-9 (Apr. 1988). .
Lang et al., Circulation 75(1): 229-234 (Jan. 1987). .
Feinstein et al., J. Am. Coll. Cardiol. 3(1): 14-20 (Jan. 1984).
.
Holland et al., J. Acoust. Soc. Am. 88(5): 2059-2069 (Nov. 1990).
.
Wheatley et al., Biomaterials 11(19): 713-7 (Nov. 1990). .
Bleeker et al., J. Ultrasound, Med. 9(8): 461-71 (Aug. 1990). .
B.D. Butler, J. clin. Ultrasound 14(5): 408-12 (Jun. 1986). .
Keller er al., J. Ultrasound Med. 5(9): 493-8 (Sept. 1986). .
Meltzer et al., J. Clin. Ultrasound 8(2): 121-7 (Apr. 1980). .
T.T. Kirn, Medical news & Perspectives, JAMA 261(11): 1542
(Mar. 17, 1989). .
Leong et al., Biomaterials, vol. 7: 364-371 (Sep. 1986). .
Tachibana K.; Tachibana S.; Albumin Microbubble Echo-Contrast
Materials as an Enhancer For Ultrasound Accelerated Thrombolysis,
Sep. 1, 1995. .
Thomas R. Porter et al.; Thrombolytic Enhancement With
Perfluorocarbon-Exposed Sonicated Dextrose Albumin Microbubbles,
Nov. 1996. .
Yunqiu Wu et al.; Binding as Lysing of Blood Clots Using MRX-408,
May 1998. .
Shiping Bao et al.; Transfection of a Reporter plasmid into
Cultured Cells By Sonoporation In Vitro. vol. 23, Nov. 6, 1997.
.
Evan C. Unger et al.; Ultrasound Enhances Gene Expression of
Liposomal Transfection. Vol. 32, No. 12, Dec. 1997. .
William J. Greenleaf et al.; Artificial Cavitation Nuclei
Significantly Enhance Acoustically Induced Cell Transfection. vol.
24, No. 4 pp. 587-595, 1998. .
F. Prat et al.; In Vivo Effects of Cavitation Alone or in
Combination Wity Chemotherapy in a Peritoneal Carcinomatosis in the
Rat. vol. 68, pp. 13-17. .
R.J. Jeffers et al.; Evaluation of the Effect of Cavitation
Activity on Drug-Ultrasound Synergisms, 1993. .
Russell Jeffers et al.; Bimethylformamide as an Enhancer of
Cavitation-Induced Cell Lysis In Vitro, vol. 97, No. 1, Jan. 1995.
.
Richard Price et al.; Delivery of Colloidal Particles and Red Blood
Cells to Tissue Through Microvessel Ruptures Created By Targeted
Microbubble Destruction With Ultrasound, Sep. 29, 1998. .
Douglas L. Miller et al; Sonoporation of Cultured Cells in the
Rotation Tube Exposure System, vol. 25, No. 1, 1999. .
Evan C. Unger et al. Acoustically Active Liposheres Containing
Paclitaxel, vol. 11, No. 12, 1992..
|
Primary Examiner: Bockelman; Mark
Attorney, Agent or Firm: Weitz; David J. Wilson Sonsini
Goodrich & Rosati
Claims
What is claim is:
1. A .[.booster.]. .Iadd.composition .Iaddend.for enhancing effects
of ultrasound in the therapy of diseases, which comprises:
.Iadd.a liquid; .Iaddend.
.[.a..]. a medicament.Iadd.; .Iaddend.and
.[.b..]. microbubbles of a gas having a diameter of 0.1 to 100
.mu.m.Iadd., .Iaddend..[.in a liquid.]. .Iadd.wherein a majority of
the medicament is present outside of the microbubbles.Iaddend..
2. The .[.booster.]. .Iadd.composition .Iaddend.according to claim
1, wherein the microbubbles are formed from air or oxygen gas in
the liquid.
3. The .[.booster.]. .Iadd.composition .Iaddend.according to claim
1, wherein the liquid is a 3 to 5% human serum albumin
solution.
4. A pharmaceutical liquid composition for the therapy of diseases
with application of ultrasound, which comprises:
.Iadd.a liquid; .Iaddend.
.[.a..]. microbubbles of a gas having a diameter of 0.1 to 100
.mu.m.Iadd.; .Iaddend.and
.[.b..]. a medicament selected from the group consisting of
thrombolytic agents, hormones, antibiotics and antineoplastic
agents.Iadd., .Iaddend..[.in a liquid.]. .Iadd.wherein a majority
of the medicament is present outside of the
microbubbles.Iaddend..
5. The composition according to claim 4, wherein the microbubbles
are formed from air or oxygen gas in the liquid.
6. The composition according to claim 4, wherein the liquid is a 3
to 5% human serum albumin solution. .[.7. The composition according
to claim 4, wherein the medicament is a member selected from
thromobolytic agents,
hormones, antibiotics, and antineoplastic agents..].8. The
composition according to claim 4, wherein the medicament is
selected from the group consisting of urokinase, tissue plasminogen
activator, insulin,
theophylline, and lidocaine. 9. A method for enhancing the
therapeutic effects of a medicament, comprising:
.[.a. applying ultrasound to a pharmaceutical liquid composition
according to claim 4 and
b..]. administering .[.said.]. .Iadd.a .Iaddend.pharmaceutical
liquid composition .Iadd.comprising a liquid, a medicament, and
microbubbles of a gas having a diameter of 0.1 to 100 .mu.m,
wherein a majority of the medicament is present outside of the
microbubbles; and
applying ultrasound to the pharmaceutical liquid
composition.Iaddend.. 10. The method according to claim 9, wherein
the liquid composition comprises about 4.times.10.sup.7 cells/ml of
microbubbles .[.of a gas having a diameter of 0.1 to 100 .mu.m and
a medicament in the liquid.]..
. The method according to claim 10, wherein the liquid is a 3 to
5%
human serum albumin solution. 12. The method according to claim 9,
wherein the medicament is selected from the group consisting of
urokinase, tissue
plasminogen activator, insulin, theophylline, and lidocaine. 13. A
method of dosing subjects with a pharmaceutical preparation by:
.[.a. applying ultrasound to a pharmaceutical liquid composition
and.].
.[.b..]. administering .[.said.]. .Iadd.a .Iaddend.pharmaceutical
liquid composition comprising .Iadd.a liquid, .Iaddend.microbubbles
of a gas having a diameter of 0.1 to 100 .mu.m.Iadd., .Iaddend.and
a medicament .[.in a liquid in the therapy of diseases.].
.Iadd.wherein a majority of the medicament is present outside of
the microbubbles; and
applying ultrasound to the pharmaceutical liquid
composition.Iaddend.. 14. The method of dosing according to claim
13, wherein the microbubbles
are formed from air or oxygen gas in the liquid. 15. The method of
dosing according to claim 13, wherein the liquid is a 3 to 5% human
serum albumin
solution. 16. The method of dosing according to claim 13, wherein
the medicament is selected from the group consisting of urokinase,
tissue
plasminogen activator, insulin, theophylline, and lidocaine.
.Iadd.17. A composition for enhancing the effects of ultrasound in
the therapy of diseases when said ultrasound is administered in
conjunction with a medicament, said composition comprising a
liquid, a medicament, and microbubbles of a gas made of a shell
having a diameter of 0.1 to 100 .mu.m, wherein a majority of the
medicament is present outside of the shell and is not incorporated
in the shell. .Iaddend..Iadd.18. A composition for enhancing the
effects of ultrasound in the therapy of diseases which comprises a
liquid, a medicament, and microbubbles of a gas made of a shell
having a diameter of 0.1 to 100 .mu.m, wherein at least a majority
of the medicament is present outside of the shell.
.Iaddend..Iadd.9. A method for enhancing the therapeutic effects of
ultrasound comprising:
creating a mixture comprising a liquid, microbubbles of a gas
having a diameter of 0.1 to 100 .mu.m, and a medicament, wherein a
majority of the medicament is present outside of the microbubbles;
and
applying ultrasound to the mixture. .Iaddend..Iadd.20. The method
of claim 19 wherein the mixture is administered in proximity to a
diseased part. .Iaddend..Iadd.21. The method of claim 19 wherein
the mixture is injected into a blood vessel near a diseased part.
.Iaddend..Iadd.22. A method for enhancing the therapeutic effect of
a medicament administered to a patient comprising:
administering to the patient a liquid composition comprising
microbubbles of a gas having a diameter of 0.1 to 100 .mu.m;
and
applying ultrasound to the liquid composition and the medicament,
wherein a majority of the medicament is present outside of the
microbubbles. .Iaddend..Iadd.23. The method of claim 22 wherein the
mixture is injected into a blood vessel near a diseased part.
.Iaddend..Iadd.24. A method of enhancing the therapeutic effects of
ultrasound of a medicament comprising:
creating microbubbles of a gas having a diameter of 0.1 to 100
.mu.m in a liquid containing the medicament, wherein a majority of
the medicament is present outside of the microbubbles; and
applying ultrasound to the microbubbles. .Iaddend..Iadd.25. The
method of claim 24 wherein the liquid is administered in the
proximity of a diseased part. .Iaddend..Iadd.26. The method of
claim 24 wherein the liquid is injected in a blood vessel near the
diseased part. .Iaddend.
Description
This invention relates to a booster useful for enhancing the
effects of ultrasound in the therapy of various diseases and a
pharmaceutical liquid composition containing the booster and a
medicament which shows enhanced diffusion and penetration of the
medicament into the body by applying ultrasound. More particularly,
it relates to a booster useful for therapy of various disease by
applying ultrasound which comprises a plenty of microbubbles of a
gas in a liquid, a pharmaceutical liquid composition comprising a
plenty of microbubbles of a gas and a medicament in a liquid, and
the use thereof in the therapy of various diseases while applying
ultrasound.
Prior Art
It is known that various diseases are remedied by the aid of
ultrasonic vibration. For example, it is described in Japanese
Patent First Publication (Kokai) No. 115591/1977, etc. that
percutaneous absorption of a medicament is enhanced by applying a
ultrasonic vibration. Japanese Patent First Publication (Kokai) No.
180275/1990 discloses a drug-injecting device which is effective on
the diffusion and penetration of the drug by applying a ultrasonic
vibration in the step of injecting a drug into a human body via a
catheter or a drug-injecting tube. U.S. Pat. Nos. 4,953,565 and
5,007,438 also disclose the technique of percutaneous absorption of
medicaments by the aid of ultrasonic vibration. It is also reported
that a tumor can be remedied by concentratedly applying ultrasound
from outside the body.
In order to enhance the therapeutic effects with ultrasound, it is
required to apply a higher energy of a ultrasonic vibration.
However, too higher energy of a ultrasonic vibration causes
disadvantageously burns or unnecessary heat at the portion other
than the desired portion. On the other hand, when the energy of a
ultrasonic vibration is lowered for eliminating such disadvantages,
there is a problem of less effect of the ultrasound at the desired
portion.
SUMMARY DESCRIPTION OF THE INVENTION
The present inventors have intensively studied on the enhancement
of the effects of ultrasound with a lower energy of a ultrasonic
vibration and have found that a booster comprising a plenty of
microbubbles of a gas in a liquid is useful for the desired
enhancement of the effects of ultrasound.
An object of the invention is to provide a booster useful for
enhancing the effects of ultrasound which comprises a plenty of
microbubbles of a gas in a liquid. Another object of the invention
is to provide a pharmaceutical liquid composition containing the
booster and a medicament which is useful for the therapy of various
diseases together with the application of ultrasound. A further
object of the invention is to provide a method for enhancing the
effects by the application of ultrasound in the therapy of various
diseases which comprises injecting the booster or the
pharmaceutical liquid composition as set forth above into the
portion to be remedied while applying ultrasound thereto. These and
other objects and advantages of the invention will be apparent to
those skilled in the art from the following description.
BRIEF DESCRIPTION OF THE DRAWING
FIG. 1 shows a schematic view of one of the micro-bubbles contained
in the booster of the invention.
FIG. 2 shows a schematic sectional view of one embodiment of a drug
administration device used for injecting, pouring, applying or
circulating the booster or the pharmaceutical liquid composition of
the invention.
FIG. 3 shows a schematic sectional view of one embodiment of a drug
administration device used for percutaneous injection of the
booster or the pharmaceutical liquid composition of the
invention.
FIG. 4 and FIG. 5 show graphs showing fibrinolysis by application
of ultrasound with or without the booster of the invention.
DETAILED DESCRIPTION OF THE INVENTION
The booster of the invention comprises a liquid containing a plenty
of microbubbles of a gas having a diameter of 0.1 to 100 .mu.m. The
microbubbles are formed by entrapping microspheres of a gas into a
liquid. The booster contains, for example, about 4.times.10.sup.7
of the microbubbles per one milliliter of a liquid. The
microbubbles are made of various gases such as air, oxygen gas,
carbon dioxide gas, inert gases (e.g. xenon, krypton, argon, neon,
helium, etc.), preferably air and oxygen gas. The liquid includes
any liquid which can form microbubbles, for example, human serum
albumin (e.g. 3 to 5% human serum albumin), a physiological saline
solution, a 5% aqueous glucose solution, an aqueous indocyanine
green solution, autoblood, an aqueous solution of maglumine
diatriazoate (=renografin), and any other X-ray contrast
medium.
The booster can be prepared by a known method, for example, by
agitating the liquid as mentioned above while blowing a gas as
mentioned above into the liquid, or alternatively exposing the
liquid to ultrasound with a sonicator under a gaseous atmosphere,
whereby a vibration is given to the liquid to form microbubbles of
the gas.
The pharmaceutical liquid composition of the invention comprises a
plenty of microbubbles of a gas and a medicament in a liquid. The
microbubbles of a gas and liquid are the same as mentioned above.
The medicament includes any known medicaments effective for the
desired therapy which can be absorbed percutaneously, for example,
anti-thrombosis agents (e.g. urakinase, tissue plasminogen
activator, etc.), hormones (e.g. insulin, etc.), theophylline,
lidocaine, antibiotics, antineoplastic agents which are sensitive
to ultrasound (e.g. doxorubicin (=adriamycin), cytarabine (=Ara-C),
etc.), and the like. The medicament can be contained in a
therapeutically effective amount as usually used. The
pharmaceutical liquid composition can be prepared by mixing a
medicament with a booster comprising a plenty of microbubbles of a
gas in a liquid. The mixing ratio may vary depending on the desired
amount and kind of the medicament and the kind of the liquid, but
is usually in a range of 1:100 to 100:1 by weight (a medicament/a
booster).
According to the invention, the therapeutic effects by ultrasound
is boosted by the presence of a booster of the invention.
Particularly, when a pharmaceutical liquid composition containing
the booster and a medicament is poured or injected into a body in
parenteral routes, such as intravenously, percutaneously or
intramuscularly, while applying thereto a ultrasonic vibration, the
therapeutic effects of the medicament is significantly enhanced.
When a ultrasound from a ultrasonic element is applied to the
liquid containing the booster and medicament, cavitation occurs in
the liquid composition, and the medicament is diffused and
penetrated into the desired portion of the biobody by the aid of
vibration induced by the cavitation. The cavitation occurs when the
level of vibration energy overs a certain threshold value. When the
ultrasound is applied to the liquid composition of the invention,
the threshold value of the vibration energy lowers due to the
presence of a plenty of microbubbles of a gas. That is, the
microbubbles of a gas act as nucleus of cavitation and thereby the
cavitation occurs more easily. Accordingly, according to the
invention, the desired ultrasonic energy necessary for the desired
diffusion and penetration of a medicament is achieved even by less
energy of ultrasonic vibration energy.
The desired ultrasound is applied by conventional ultrasonic
devices which can supply a ultrasonic signal of 20 KHz to several
MHz.
With reference to the accompanying drawing, the invention is
illustrated in more detail.
FIG. 1 shows a schematic view of one of the plenty of microbubbles
of a gas contained in the booster of the invention, wherein the
microbubble of a gas has a diameter of 0.1 to 100 .mu.m and is
composed of a shell of human serum albumin (1) and gas (2)
entrapped within the microbubble. The microbubbles are contained in
a liquid (3) such as 5% human serum albumin solution in an amount
of, for example, above 4.times.10.sup.7 cells/ml.
The booster is mixed with a medicament to give a pharmaceutical
liquid composition. The pharmaceutical liquid composition is
directly administered to the diseased part with an appropriate
device, for example, with a drug administration device (4) as shown
in FIG. 2. The drug administration device (4) comprises a base tube
(5) to which the pharmaceutical liquid composition is supplied, and
an end tube (6) which is to be inserted into the tissue of the
biobody and through which the pharmaceutical liquid composition is
poured or injected into the diseased part. The end tube (6) is
provided with a ultrasonic element (7) (e.g. a cylindrical ceramic
oscillator, etc.). The ultrasonic element (7) is supplied by a
ultrasonic signal of 20 kHz to several MHz from a ultrasonic
oscillation circuit (8) via a conductor (9a), connectors (10a) and
(10b) provided on the side of the base tube (5), a part of the base
tube (5) and a conductor (9b) provided within the end tube (6).
The application or injection of a medicament is carried out in the
form of a pharmaceutical liquid composition which is prepared by
previously mixing the medicament with the booster comprising a
plenty of microbubbles of a gas in a liquid, wherein the medicament
and the booster are mixed in a ratio of 1:100 to 100:1 by weight.
The pharmaceutical liquid composition is poured into the base tube
(5) from the supply opening (11) provided on the tip of the base
tube (5), passes through a flow path (12) within the base tube (5)
and a flow path (13) within the end tube (6) and then administered
to the diseased part or the portion close thereto of the patient
via a pouring opening (14) provided at the bottom of the end tube
(6).
When the pharmaceutical liquid composition is administered into the
diseased part or the portion close thereto through the pouring
opening (14), a ultrasonic energy generated from a ultrasonic
element (7) is given to the liquid composition, by which cavitation
occurs owing to the ultrasonic energy. Microbubbles are formed at
the occurrence of cavitation and when the microbubbles are
decomposed, energy is generated, by which diffusion and penetration
of the medicament is promoted. Since the pharmaceutical liquid
composition contains a plenty of microbubbles of a gas, the
microbubbles act as a nucleus for the cavitation, by which the
cavitation occurs more easily, in other words, the threshold value
of occurrence of cavitation lowers. Accordingly, it is possible to
generate the cavitation with less energy than the case of using no
booster.
When a ultrasonic vibration is applied to a liquid, if the liquid
contains any material being able to become a nucleus, the
cavitation occurs generally at a lower threshold value of energy,
but it has been found that the cavitation occurs most easily where
the liquid contains microbubbles of a gas having a diameter of 0.1
to 100 .mu.m.
The drug administration device (4) as shown in FIG. 2 can be used,
for example, for administering a pharmaceutical liquid composition
into a blood vessel. For instance, in the treatment of coronary
thrombosis, a pharmaceutical liquid composition comprising a
booster of the invention and a urokinase is injected into the part
of thrombosis or the close portion thereof with the drug
administration device (4) where the tip of the end tube (6) is
inserted into the portion close to the thrombosis with applying
ultrasound, by which the thrombolytic effects of the medicament are
significantly increased and further the blood flow is recovered
within a shorter period of time in comparison with the
administration of the medicament without the booster. The drug
administation device (4) may also be used for the removing hematoma
in bleeding of brain. For example, a pharmaceutical liquid
composition comprising a booster of the invention and a thromolytic
agent (e.g. urokinase) is administered to the portion of hematoma
with the drug administration device (4) with applying ultrasound
like the above, by which the hematoma is easily lysed.
In another embodiment of the invention, the pharmaceutical liquid
composition can be administered percutaneously with a drug
administration device (15) as shown in FIG. 3.
In the drug administration device (15) suitable for percutaneous
administration of a medicament, a layer of a medicament (17) is
provided below a ultrasonic element (16) (e.g. a disc shaped
ceramic oscillator, etc.), under of which an adhesive layer (18)
having a medicament permeability is laminated, whole of which is
covered with a plastic cover (19). The ultrasonic element (16) is
supplied by ultrasonic signal from a ultrasonic oscillation circuit
provided outside via a connector (20) like in the drug
administration device (4) as shown in FIG. 2.
In the device (15) of FIG. 3, a pharmaceutical liquid composition
comprising a mixture of a booster and a medicament is contained in
the layer of a medicament (17). When this device (15) is used, it
is adhered onto the skin with facing the adhesive layer (18) to the
skin, and then a ultrasonic signal is supplied to the ultrasonic
element (16), by which a
ultrasonic vibration from the ultrasonic element (16) is given to
both of the medicament layer (17) and the skin and thereby the
medicament contained in the medicament layer (17) is passed through
the skin and is penetrated into the tissue to be treated. In this
embodiment, since microbubbles of a gas are contained in the
medicament layer (17), cavitation occurs easily within the
medicament layer (17) by application of ultrasound, and hence even
lower energy of the ultrasonic vibration is supplied from the
ultrasonic element (16), the diffusion and penetration of the
medicament can effectively be done to result in rapid absorption of
the medicament.
The booster of the invention may also be used alone without mixing
with a medicament in the therapy with ultrasound. For example, in
the therapy of tumors by heating the diseased part of the tissue
with ultrasound, that is, by concentratedly applying a ultrasonic
vibration outside the biobody, a booster comprising a plenty of
microbubbles of a gas in a liquid of the invention is previously
injected into the blood vessel or to the portion close to the
diseased part before application of ultrasound, by which the effect
of heating with ultrasound is enhanced and thereby the therapeutic
effects are significantly improved. In this embodiment, cavitation
occurs also by the ultrasonic vibration more easily because of
using a liquid containing microbubbles of a gas, and hence, even by
less energy of the ultrasonic vibration suppled from the ultrasonic
element, the ultrasonic energy sufficient to the therapy is
obtained and thereby the undesirable burns and unnecessary heating
at other portions can be avoided.
In the treatment of tumors, it is, of course, more effective to use
it together with a chemotherapeutic agent suitable for the
treatment of the tumors, by which the effects of the
chemotherapeutic agent are more enhanced, where the diffusion and
penetration of the medicament are improved owing to the
booster.
The substance such as human serum albumin in the booster of the
invention is easily metabolized within the biobody and excreted
outside the biobody, and hence, it is not harmful to human body.
Besides, the gas trapped within the microbubbles is extremely small
and is easily dissolved in the blood fluid. Accordingly, the
booster of the invention has no problem in the safety thereof.
The preparation of the booster and pharmaceutical liquid
composition of the invention and effects thereof are illustrated by
the following Examples and Experiment, but it should not be
construed to be limited thereto.
EXAMPLE 1
Preparation of a Booster:
A 5% human serum albumin (8 ml) in a 10 ml-volume syringe is
exposed to ultrasound with a sonicator (frequency, 20 KHz) by which
vibration is given to the human serum albumin and a plenty of
microbubbles of air are formed in the human serum albumin to give a
booster comprising a human serum albumin containing a plenty of
microbubbles of air.
EXAMPLE 2
Preparation of a Pharmaceutical Liquid Composition:
The 5% human serum albumin containing a plenty of microbubbles of
air prepared in Example 1 is mixed with urokinase (concentration
1200 IU/ml) to give the desired pharmaceutical liquid
composition.
Experiment
1. Forming Artificial Thrombosis
An artificial thrombosis was formed by Chandler's method. A blood
(1 ml) collected from healthy human (two persons) was entered into
a flexibale tube (inside diameter 3 mm, length 265 mm) and thereto
was added calcium chloride, and then the tube was made a loop like
shape, which was rotated at 12 r.p.m. for 20 minutes to give an
artificial thrombosis model.
2. Ultrasonic Catheter
A ceramic ultrasonic element (width 2 mm, length 5 mm, thickness 1
mm) was inserted into the tip of a cetheter (diameter 2 mm), and an
oscillating element was connected to an oscillator provided outside
with a fine connector passed through the catheter. A fine tube for
pouring a test solution was provided at an opening opposite to the
opening of the catheter end.
3. Test Method
The artificial thrombosis prepared above was added to a test tube
together with a blood, and the ultrasonic catheter was inserted
into the test tube so that the end of the catheter was set close to
the portion of the artificial thrombosis (at a distance of about 5
mm), and to the test tube a mixture of urokinase and a booster
prepared in Example 1 was added at a rate of 1 ml per minute,
wherein urokinase (concentration 1200 IU/ml) and the booster were
mixed immediately before pouring at a mixing ratio of 1:1 by
weight. The mixture was refluxed while keeping the volume of the
test solution at a constant level by removing excess volume of the
solution by suction. The ultrasound (170 KHz) was exposed to the
mixture by a pulse method (exposed for 2 seconds and stopped for 4
seconds) for 2 minutes (total exposing time 40 seconds). After the
exposure, the ultrasonic catheter was removed from the test tube,
and the mixture was incubated at 37.degree. C. for 5 to 120
minutes, washed with a physiological saline solution several times
and dried overnight. Thereafter, the dried mixture was weighed. As
a control, the above was repeated by using only a physiological
saline solution.
4. Test Results
The rate of fibrinolysis was calculated by the following equation:
##EQU1##
The results are shown in the accompanying FIGS. 4 and 5 wherein
there are shown in average of twice tests.
FIG. 4 shows the results in the thrombosis prepared by using blood
collected from one person, wherein the symbol -- is the data
obtained in the addition of urokinase alone without exposure of
ultrasound, - .diamond-solid.- is the data obtained in the addition
of urokinase alone with exposure of ultrasound, and -.box-solid.-
is the data obtained in the addition of a mixture of urokinase and
the booster with exposure of ultrasound.
As is shown in FIG. 4, the time for achieving 20% fibrinolysis was
45 minutes by urokinase alone without exposure of ultrasound, 30
minutes by a combination of urokinase and exposure of ultrasound,
and only 10 minutes by a combination of a mixture of urokinase and
a booster and exposure of ultrasound. The fibrinolytic effects of
urokinase (both the rate of fibrinolysis and the fibrinlytic time)
were signigicantly enhanced by using a booster with application of
ultrasound.
FIG. 5 shows the results in the thrombosis prepared by using blood
collected from another person and with reduced energy of ultrasound
by 15%, wherein the symbols are the same as in FIG. 4. As is shown
in FIG. 5, the fibrinolytic effects were significantly enhanced by
using a mixture of urokinase and the booster. That is, in case of
using urokinase alone with exposure of ultrasound, the 50%
fibrinolysis was achieved by the treatment for 60 minutes, but in
case of using a mixture of urokinase and the booster with exposure
of ultrasound, it reduced to one fourth, i.e. it was achieved by
the treatment only for 15 minutes.
* * * * *